Italia markets closed
FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.360,21 +506,99 (+0,86%)
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Prezzo in tempo reale. Valuta in INR.
Aggiungi a watchlist
Alla chiusura: 03:30PM IST
| Chiusura precedente | 1.520,15 |
| Aperto | 1.531,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 1.500,05 - 1.532,00 |
| Intervallo di 52 settimane | 922,45 - 1.638,85 |
| Volume | |
| Media Volume | 2.815.469 |
| Capitalizzazione | 3,615T |
| Beta (5 anni mensile) | 0,53 |
| Rapporto PE (ttm) | 40,65 |
| EPS (ttm) | 37,06 |
| Prossima data utili | 24 mag 2024 - 28 mag 2024 |
| Rendimento e dividendo (futuro) | 12,50 (0,83%) |
| Data ex dividendo | 09 feb 2024 |
| Stima target 1A | 829,22 |
GlobeNewswireNidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern
© 2024 Yahoo. Tutti i diritti riservati.